Yahoo! Finance Search - Finance Home - Yahoo! - Help

Wednesday, December 2 2009 2:11pm ET - U.S. Markets close in 1 hour and 49 minutes.
Industry Center - Biotechnology
Industry Center > Biotechnology > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Biotechnology News
View: Latest News | Top Stories
1. Dyax shares rocket on FDA clearance for Kalbitor - AP - 2 hours, 42 minutes ago
Shares of Dyax Corp. jumped to their highest price in more than a year on Wednesday after regulators approved marketing of the company's hereditary angioedema drug Kalbitor.
2. CytRx Corporation (NASDAQ: CYTR) Looking More Like a Solid Rebound Play - Marketwire - Wed 11:05 am ET
3. Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial - PR Newswire - Wed 9:30 am ET
Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme , the deadliest form of brain cancer.
4. Hemispherx Biopharma Announces Investor Conference Call - GlobeNewswire - Wed 8:30 am ET
PHILADELPHIA -- Hemispherx Biopharma, Inc. announces an investor update by teleconference on Thursday, December 3, 2009 at 10:00am EST. The update will cover regulatory status of its platform technology (Ampligen, Alferon-N, Alferon LDO), strategic partnering and other matters, followed by a Q and A period.
5. PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share - PR Newswire - Wed 8:30 am ET
PDL BioPharma, Inc. today announced that it has established the per share amount of the previously announced $200 million special dividend as $1.67 per share. The dividend will be paid on December 15, 2009 to all holders of the Company's stock as of the December 1, 2009 record date.
6. Novavax swine flu vaccine meets study goal - AP - Wed 8:27 am ET
Novavax Inc. said Wednesday that the swine flu vaccine it's developing prompted an immune system response in patients during a midstage study being conducted in Mexico.
7. Genta to Support Initiation of New Clinical Trial using Ganite® as Treatment for Life-Threatening Infections in Patients with Cystic Fibrosis - Business Wire - Wed 8:02 am ET
BERKELEY HEIGHTS, N.J.----Genta Incorporated announced that the Company will supply Ganite® for a new clinical trial that will be initiated in patients with cystic fibrosis who may develop serious infections.
8. Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome - GlobeNewswire - Tue 4:30 pm ET
PHILADELPHIA -- Hemispherx Biopharma, Inc. , announced that it received a Complete Response Letter from the U.S. Food and Drug Administration which describes specific additional recommendations related to the Ampligen NDA.
9. Emerging Stock Report Initiates Independent Research Coverage On ADVENTRX Pharmaceuticals, Inc. - GlobeNewswire - Tue 11:19 am ET
CALGARY, Alberta -- Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on ADVENTRX Pharmaceuticals, Inc. . Emerging Stock Report is currently offering a complimentary trial subscription to the investment community.
10. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine - PR Newswire - Tue 10:15 am ET
CEL-SCI Corporation , a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.
Sponsor Results
$74/Hr Job - 117 Openings (Swine Flu)
Can You Type? Earn $74+/hr From Home. Seen On CNN & FOX News.
www.News9Tonight.com
Top Biotechnology Stocks
3 Pharmaceutical Companies To Invest In Now! Get The Free Report.
www.Fool.com
Minuteclinic H1N1 Flu
Get important information on H1N1 and learn how MinuteClinic can help.
www.MinuteClinic.com/Flu
(What's This?)
  

RSS Feeds

Add headlines to your
personalized My Yahoo! Page
( About My Yahoo! and RSS )

Biotechnology Headlines
More Finance RSS Feeds


Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2009 Morningstar, Inc. All Rights Reserved. Company information © 2009 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2009, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo! nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo! site, a user agrees not to redistribute the information found therein.

Questions or Comments?